Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AFIRMELLE vs GANIRELIX ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Prevention of pregnancy (FDA-approved)
Inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART),Off-label: Treatment of hormone-sensitive cancers (e.g., prostate cancer) when rapid suppression of gonadotropins is needed
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Terminal elimination half-life is approximately 16.2 hours (range 11-19 hours) in healthy females; clinically supports once-daily dosing.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Primarily hepatically metabolized via peptide hydrolysis; no major CYP450 involvement.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Renal (approximately 75% as unchanged drug and metabolites) and fecal (approximately 22%).
~99% bound to serum albumin and sex hormone-binding globulin.
Approximately 90%, primarily to albumin and alpha-1-acid glycoprotein.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Approximately 0.9 L/kg, indicating distribution primarily into extracellular fluid and some tissue binding.
Oral: ~70% due to first-pass metabolism.
Subcutaneous: Approximately 100% (range 91-100%) relative to intravenous injection.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment. No data for severe renal impairment (Cr Cl < 30 m L/min).
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
No clinical data for hepatic impairment. Use with caution in moderate to severe hepatic impairment.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not approved for use in pediatric patients.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Not approved for use in geriatric patients.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
None
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Hypersensitivity reactions (urticaria, angioedema) have been reported,Ovarian hyperstimulation syndrome (OHSS) may occur with ART,Congenital abnormalities cannot be excluded; pregnancy should be excluded before use
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Hypersensitivity to ganirelix or any component,Known or suspected pregnancy,Lactation (not recommended due to potential neonatal effects)
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
No significant food interactions. Grapefruit may theoretically affect metabolism but data are lacking; caution is advised.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) due to hormonal disruption.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Unknown if excreted in human breast milk; M/P ratio not available. Risk of adverse effects in infant due to potential hormonal activity. Use caution; avoid if possible.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
No dose adjustments in pregnancy; contraindicated. If inadvertently used, discontinue immediately; no study on pharmacokinetic changes in pregnancy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Administer subcutaneously in the abdomen. Rotate injection sites to prevent lipodystrophy. Monitor for ovarian hyperstimulation syndrome (OHSS) especially in patients with polycystic ovary syndrome. Use caution in patients with renal impairment.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
Inject exactly as prescribed, typically once daily during the stimulation phase.,Do not skip doses; missed doses may reduce effectiveness.,Report severe pelvic pain, nausea, vomiting, or rapid weight gain immediately.,Store at room temperature (20-25°C) and protect from light.,Use within 30 days after first use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AFIRMELLE vs GANIRELIX ACETATE, answered by our medical review team.
AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. GANIRELIX ACETATE is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AFIRMELLE and GANIRELIX ACETATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of GANIRELIX ACETATE is: 250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AFIRMELLE and GANIRELIX ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. GANIRELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.